| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/03/2003 | WO2003000238A1 Pharmaceutical compositions of adsorbates of amorphous drug |
| 01/03/2003 | WO2003000195A2 Method and material for treating immune diseases |
| 01/03/2003 | WO2003000185A2 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/03/2003 | WO2003000183A2 Method of treating atherosclerosis and other inflammatory diseases |
| 01/03/2003 | WO2003000181A2 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | WO2003000180A2 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | WO2003000177A2 Stable controlled release pharmaceutical compositions containing pravastatin |
| 01/03/2003 | WO2003000014A2 Spherical protein particles and methods of making and using them |
| 01/03/2003 | WO2003000009A2 Stimulation of vascularization with vegf-b |
| 01/03/2003 | WO2002087605A3 Modified fvii in treatment of ards |
| 01/03/2003 | WO2002083667A3 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 01/03/2003 | WO2002080914A3 Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments |
| 01/03/2003 | WO2002072584A3 Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders |
| 01/03/2003 | WO2002058682A3 An anti-atherosclerosis composition containing carotenoids and method for inhibiting ldl oxidation |
| 01/03/2003 | WO2002056915A3 Complex of modafinil and cyclodextrin |
| 01/03/2003 | WO2002047673A3 Methods and compositions to treat conditions associated with neovascularization |
| 01/03/2003 | WO2002046170A8 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 01/03/2003 | WO2002045702A3 Tricyclic therapeutics for chemokine mediated diseases |
| 01/03/2003 | WO2002034741A3 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
| 01/03/2003 | WO2002012501A3 Anti-dual integrin antibodies, compositions, methods and uses |
| 01/03/2003 | WO2002012471A3 Angiotensin converting enzyme homolog and uses therefor |
| 01/03/2003 | WO2002010387A3 G-protein coupled receptors |
| 01/03/2003 | WO2002009761A3 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| 01/03/2003 | WO2002002757A3 Adenylyl and guanylyl cyclases |
| 01/03/2003 | WO2002002603A3 Protein modification and maintenance molecules |
| 01/03/2003 | WO2002000728A3 Methods and compositions for isolating biologically active antibodies |
| 01/03/2003 | WO2001098331A3 Glucagon-like peptide-1 analogs |
| 01/03/2003 | CA2455292A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | CA2451885A1 Method and material for treating immune diseases |
| 01/03/2003 | CA2451686A1 A novel g protein-coupled receptor, gave 3 |
| 01/03/2003 | CA2451664A1 Use of bicyclo compounds for treating alzheimer's disease |
| 01/03/2003 | CA2451625A1 Substituted n-acyl-aniline derivatives, the preparation thereof and the use thereof as pharmaceutical compositions |
| 01/03/2003 | CA2451311A1 Stimulation of vascularization with vegf-b |
| 01/03/2003 | CA2451250A1 Modulating serum amyloid a interaction with tanis and agents useful for same |
| 01/03/2003 | CA2451185A1 Spherical protein particles and methods of making and using them |
| 01/03/2003 | CA2450969A1 Nucleic acid-associated proteins |
| 01/03/2003 | CA2450954A1 Method of treating atherosclerosis and other inflammatory diseases |
| 01/03/2003 | CA2450925A1 G-protein coupled receptors |
| 01/03/2003 | CA2450921A1 Protein modification and maintenance molecules |
| 01/03/2003 | CA2450828A1 Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin |
| 01/03/2003 | CA2450579A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2450562A1 Tyrosine kinase inhibitors |
| 01/03/2003 | CA2450541A1 Substituted benzopyran derivatives against arrhythmia |
| 01/03/2003 | CA2450491A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | CA2450478A1 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/03/2003 | CA2450475A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2450449A1 Pharmaceutical formulation |
| 01/03/2003 | CA2450174A1 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 01/03/2003 | CA2450001A1 Stable pharmaceutical compositions containing pravastatin |
| 01/03/2003 | CA2449998A1 Stable controlled release pharmaceutical compositions containing pravastatin |
| 01/03/2003 | CA2449844A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 01/02/2003 | WO2002002529A1 Bicyclic lactams and sulfonamides with 5-ht1a-affinity and use thereof for preventing and treating cerebral ischaemia |
| 01/02/2003 | US20030004355 Regulating intracellular levels of cyclic guanosine-3*,5*-monophosphate by activiating soluble guanylate cyclase or inhibiting phosphodiesterases |
| 01/02/2003 | US20030004351 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
| 01/02/2003 | US20030004350 Pyrrolo(2,3-b)pyridine derivatives; anticancer and antiproliferative agents |
| 01/02/2003 | US20030004344 Thrombin or factor Xa inhibitors |
| 01/02/2003 | US20030004327 Cerebellum and embryo specific protein |
| 01/02/2003 | US20030004317 Nucleic acids encoding anti-human alphanubeta3 and alphanubeta5 antibodies |
| 01/02/2003 | US20030004206 Hypotensive agents; cardiovascular disorders |
| 01/02/2003 | US20030004205 Carvedilol-hydrophilic solutions |
| 01/02/2003 | US20030004196 Antiinflamamtory agents; autoimmune disease |
| 01/02/2003 | US20030004194 Method for treating fibrotic diseases or other indications VI |
| 01/02/2003 | US20030004193 Immunomodulators; antiinflammatory agents |
| 01/02/2003 | US20030004186 Anticoagulants; cardiovascular disorders; central nervous system disorders |
| 01/02/2003 | US20030004174 Antiinflammatory agents, anticancer agents, antihistamines, central nervous system disorders |
| 01/02/2003 | US20030004172 Cardiovascular disorders, osteoporosis, multiple sclerosis, antiarthritic agents |
| 01/02/2003 | US20030004168 Mixture of hypotensive agent and calcium channel blockers; cardiovascular disorders |
| 01/02/2003 | US20030004167 Imidazo-heterobicycles as factor Xa inhibitors |
| 01/02/2003 | US20030004166 Novel triazine compounds useful as sorbitol dehydrogenase inhibitors |
| 01/02/2003 | US20030004165 Polyazanaphthalene compounds and pharmaceutical use thereof |
| 01/02/2003 | US20030004164 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004161 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004156 Anticholesterol agents; cardiovascular disorders; antidiabetic agents; antiproliferative agents |
| 01/02/2003 | US20030004153 Novel heteroaryl-diazabicycloalkanes |
| 01/02/2003 | US20030004152 Method of treating sexual disturbances |
| 01/02/2003 | US20030004151 Cyclic derivatives as modulators of chemokine receptor activity |
| 01/02/2003 | US20030004147 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
| 01/02/2003 | US20030004146 Compositions for preventing hormone induced adverse effects |
| 01/02/2003 | US20030004144 Anticancer agents; skin disorders |
| 01/02/2003 | US20030004137 Muscle relaxants, controlling immunology, strokes, antidiabetic agents |
| 01/02/2003 | US20030004132 Binding to galectins; therapy for autoimmune disease |
| 01/02/2003 | US20030004110 Therapeutic compositions and methods for enhancing angiogenesis |
| 01/02/2003 | US20030003545 Nucleotide sequences coding polypeptide for use in the treatment of immunological defects |
| 01/02/2003 | US20030003532 Novel nucleic acid sequences encoding human slit-, megf-, and roundabout-like polypeptides |
| 01/02/2003 | US20030003470 Kit for use in the diagnosis of hypertension; obtain sample, determine pattern of alleles, detect preferential gene expression, preferential gene expression indicates hypertension |
| 01/02/2003 | US20030003462 Novel human interleukin-like proteins and polynucleotides encoding them |
| 01/02/2003 | US20030003169 Prepared by fermenting an aqueous Glycine max (L.) extract with at least one lactic acid bacteria together with at least one yeast |
| 01/02/2003 | US20030003141 Contacting a blood vessel wall cell with an A beta 40 inhibitor, such that cerebral amyloid angiopathy is inhibited |
| 01/02/2003 | US20030003094 Compound which disrupts microtubule function and polymeric carrier, with proviso that polymeric carrier is not a capsule |
| 01/02/2003 | US20030003082 Use of poly-Glu,Tyr and T cells treated therewith for neuroprotective therapy |
| 01/02/2003 | US20030003077 A genetic engineered adenoviral vector contains an adenoviral genome from which the open reading frames E1 and/or E3 were deleted and a therapeutic gene or a DNA sequence that encodes for therapeutic proteins useful in fibrosis treatment |
| 01/02/2003 | US20030003056 Useful in in vivo applications sucha as embolizing blood vessels and/or reversibly sterilizing mammals |
| 01/02/2003 | EP1270585A1 Peptide derivative |
| 01/02/2003 | EP1270576A2 3-phenyl-3,7-diazabicyclo[3,3,1]nonanes, process for their preparation and pharmaceutical compositions containing them |
| 01/02/2003 | EP1270570A1 Amide compounds and use thereof |
| 01/02/2003 | EP1270569A1 Substituted tryptophan derivatives |
| 01/02/2003 | EP1270567A1 Pyrazoline derivatives or tetrahydropyridazine derivatives and medicinal use thereof |
| 01/02/2003 | EP1270559A1 Novel imidazole derivatives with anti-inflammatory activity |
| 01/02/2003 | EP1270558A1 "Compound for the treatment of atherosclerotic-thrombotic pathological conditions" |
| 01/02/2003 | EP1270551A1 Urea derivatives with antiproteolytic activity |